
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Adaptive Biotechnologies Corp is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$8.24 – an increase of 6.32% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Adaptive Biotechnologies
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Adaptive Biotechnologies. Find the share by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$8.24, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks

Our top pick for
Long-term investing

Our top pick for
Low-cost broker

What's in this guide?
- Adaptive Biotechnologies key stats
- Compare share trading platforms
- Is Adaptive Biotechnologies stock a buy or sell?
- Adaptive Biotechnologies performance over time
- Adaptive Biotechnologies's financials
- How volatile are Adaptive Biotechnologies shares?
- Does Adaptive Biotechnologies pay a dividend?
- Other common questions
Adaptive Biotechnologies stock price (NASDAQ:ADPT)
Use our graph to track the performance of ADPT stocks over time.Adaptive Biotechnologies shares at a glance
52-week range | US$5.955 - US$43.397 |
---|---|
50-day moving average | US$8.1275 |
200-day moving average | US$20.1999 |
Target price | US$15.3 |
PE ratio | N/A |
Dividend yield | US$0 (0%) |
Earnings per share (TTM) | US$-1.626 |
Compare trading apps to buy Adaptive Biotechnologies shares
Is it a good time to buy Adaptive Biotechnologies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Adaptive Biotechnologies price performance over time
Historical closes compared with the last close of $8.24
1 week (2022-06-23) | -5.29% |
---|---|
1 month (2022-05-26) | 8.85% |
6 months (2021-12-30) | -70.91% |
1 year (2021-06-30) | -79.83% |
---|---|
2 years (2020-06-30) | -82.97% |
3 years (2019-06-28) | -82.94% |
Stocks similar to Adaptive Biotechnologies
Adaptive Biotechnologies financials
Revenue TTM | US$154.5 million |
---|---|
Gross profit TTM | US$91 million |
Return on assets TTM | -14.94% |
Return on equity TTM | -35.88% |
Profit margin | -148.44% |
Book value | 3.891 |
Market capitalisation | US$1.2 billion |
TTM: trailing 12 months
Adaptive Biotechnologies share dividends
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Adaptive Biotechnologies share price volatility
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as US$5.955 up to US$43.397. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 1.0667. This would suggest that Adaptive Biotechnologies's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Adaptive Biotechnologies overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies in the news
Microsoft-Developed Covid Tech Can Now Detect Lyme Disease
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
Frequently asked questions
More guides on Finder
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
-
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
-
How to buy Besra Gold (BEZ) shares
Steps to owning and managing Besra Gold shares.
-
How to buy The Lottery Corporation (TLC) shares
Steps to owning and managing The Lottery Corporation shares.
Ask an Expert